<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="218925">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234338</url>
  </required_header>
  <id_info>
    <org_study_id>101850</org_study_id>
    <nct_id>NCT00234338</nct_id>
  </id_info>
  <brief_title>Study Evaluating Prevenar in High-Risk Children</brief_title>
  <official_title>Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the local and systemic tolerability of Prevenar in
      children ages 2 to 5 years old in usual care settings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Pneumococcal Disease</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High-risk children ages 2 to 5 years old

        Exclusion criteria:

          -  Prior administration of Prevenar

          -  Prior and/or concurrent administration of 23 vPs vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Germany, MedInfoDEU@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <lastchanged_date>December 7, 2007</lastchanged_date>
  <firstreceived_date>October 4, 2005</firstreceived_date>
  <keyword>Children</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Prevenar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
